Publicação
Efficacy and safety of topical antifungals used in the treatment of vaginal fungal infections: A Systematic Review of clinical trials published between 2018 and 2024
| Resumo: | Genitourinary infections are clinically important due to the discomforting symptoms, psychological repercussions, and the ease of acquisition and transmission of the human immunodeficiency virus [1]. Vulvovaginal candidiasis is the second leading cause of vaginitis and affects 75% of women worldwide. The aim of this study is to analyse the efficacy and safety of the latest topical antifungals for vaginal fungal infections. Literature searches were performed in the PubMed, Scopus, LILACS, and IBECS databases, according to the PRISMA guidelines. Following the removal of duplicate records, a total of 1326 studies were screened based on predefined inclusion and exclusion criteria. Studies published between 2018 and 2024 were included. This systematic review is registered in the PROSPERO database under the registration number CRD42024527596. Ultimately, 18 studies fulfilled these criteria and were incorporated into the systematic review. Of the 18 clinical trials analysed, 16 assessed topical application alternatives to conventional treatment of genitourinary infections. The comparison between the investigational products and the control groups demonstrated that, overall, the tested products exhibit efficacy comparable to or greater than that of conventional treatments in the management of genitourinary infections. In 14 of the 18 clinical trials included in the systematic review, no adverse effects were reported. Natural topical treatments for vulvovaginal candidiasis show promising efficacy, better tolerability, and greater patient convenience, suggesting potential to improve adherence and contributing to strategies against antifungal resistance. |
|---|---|
| Autores principais: | Oliveira, Tiago |
| Outros Autores: | Jesus, Ângelo; Moreira, Fernando; Jesus, Ângelo; Moreira, Fernando |
| Assunto: | Genitourinary infections Vulvovaginal candidiasis Antifungals |
| Ano: | 2025 |
| País: | Portugal |
| Tipo de documento: | documento de conferência |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Instituto Politécnico do Porto |
| Idioma: | inglês |
| Origem: | Repositório Científico do Instituto Politécnico do Porto |
| Resumo: | Genitourinary infections are clinically important due to the discomforting symptoms, psychological repercussions, and the ease of acquisition and transmission of the human immunodeficiency virus [1]. Vulvovaginal candidiasis is the second leading cause of vaginitis and affects 75% of women worldwide. The aim of this study is to analyse the efficacy and safety of the latest topical antifungals for vaginal fungal infections. Literature searches were performed in the PubMed, Scopus, LILACS, and IBECS databases, according to the PRISMA guidelines. Following the removal of duplicate records, a total of 1326 studies were screened based on predefined inclusion and exclusion criteria. Studies published between 2018 and 2024 were included. This systematic review is registered in the PROSPERO database under the registration number CRD42024527596. Ultimately, 18 studies fulfilled these criteria and were incorporated into the systematic review. Of the 18 clinical trials analysed, 16 assessed topical application alternatives to conventional treatment of genitourinary infections. The comparison between the investigational products and the control groups demonstrated that, overall, the tested products exhibit efficacy comparable to or greater than that of conventional treatments in the management of genitourinary infections. In 14 of the 18 clinical trials included in the systematic review, no adverse effects were reported. Natural topical treatments for vulvovaginal candidiasis show promising efficacy, better tolerability, and greater patient convenience, suggesting potential to improve adherence and contributing to strategies against antifungal resistance. |
|---|
Atividades financiadas
Não foram encontrados projetos financiados.